Financials in USD. Standardized financial statements.
A compact view of how Allergy Therapeutics plc turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $75.56M | $55.20M | $59.59M | $72.77M | $84.33M | $78.20M | $73.72M | $68.35M | $64.14M | $48.51M |
| Revenue Growth? | +36.9% | -7.4% | -18.1% | -13.7% | +7.8% | +6.1% | +7.9% | +6.6% | +32.2% | 0.0% |
| Cost of Revenue? | $41.07M | $25.46M | $26.34M | $23.26M | $22.11M | $20.20M | $18.38M | $17.01M | $16.77M | $14.07M |
| Gross Profit? | $34.50M | $29.74M | $33.24M | $49.51M | $62.23M | $58.00M | $55.34M | $51.33M | $47.37M | $34.44M |
| Gross Margin? | +45.7% | +53.9% | +55.8% | +68.0% | +73.8% | +74.2% | +75.1% | +75.1% | +73.9% | +71.0% |
| Operating Expenses? | $75.00M | $64.99M | $72.90M | $61.75M | $58.19M | $49.69M | $50.95M | $58.06M | $49.26M | $46.39M |
| Operating Income? | -$28.16M | -$35.26M | -$39.65M | -$12.24M | $4.03M | $8.31M | $4.39M | -$6.73M | -$1.90M | -$11.95M |
| EBITDA? | -$40.40M | -$30.74M | -$35.10M | -$7.82M | $8.28M | $12.49M | $6.58M | -$4.56M | $191,000 | -$10.56M |
| Income Before Tax | -$39.20M | -$39.17M | -$41.77M | -$12.66M | $3.66M | $8.07M | $4.29M | -$6.90M | -$1.97M | -$12.06M |
| Income Tax Expense | $932,000 | $1.05M | $1.30M | $1.12M | $771,000 | $1.01M | $826,000 | $637,000 | $511,000 | $1.01M |
| Net Income? | -$55.09M | -$40.22M | -$43.07M | -$13.78M | $2.89M | $7.06M | $3.47M | -$7.53M | -$2.48M | -$13.07M |
| EPS? | $-0.01 | $-0.01 | $-0.04 | $-0.01 | $0.00 | $0.01 | $0.00 | $-0.01 | $-0.00 | $-0.01 |
| Diluted EPS? | $-0.01 | $-0.01 | $-0.04 | $-0.01 | $0.00 | $0.01 | $0.00 | $-0.01 | $-0.00 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality